CME: Advances in the Standard of Care in TNBC: Addressing Health Disparities and Integrating ADCs Into Treatment

Advances in the Standard of Care in TNBC: Addressing Health Disparities and Integrating ADCs Into Treatment

Take Post-Test

If you’ve already completed the activity.

Overview
For patients with recurrent unresectable or metastatic triple negative breast cancer (TNBC), standard systemic therapy has largely consisted of chemotherapy, though the outlook has improved recently following FDA approval of several targeted therapies and immunotherapeutic options. The management of TNBC remains quite challenging for clinicians, particularly in light of persistent disparities in TNBC care that disproportionately impact specific patient populations (eg, women of minoritized populations). Racial disparities specific to TNBC include a higher incidence, more advanced stage at diagnosis, and increased mortality among black women versus white women in the United States.
This web-based, on-demand, activity will review health disparities and inequities in TNBC and how they impact care, along with the latest evidence for current and emerging antibody-drug conjugates and immunotherapeutic agents, to assist oncology professionals in delivering impartial care to all patients.
Disclosure of Conflicts of Interest
Disclosure of Conflict of Interest
AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers, and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity.
AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months: Ricki Fairley, BA, MBA, reported a financial interest/relationship or affiliation in the form of Grant: Novartis Pharmaceuticals Corp; Genentech, Inc; Gilead; and Eisai Inc. Sara M. Tolaney, MD, MPH, reported a financial interest/relationship or affiliation in the form of Consultant/Advisory boards: AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Merck & Co., Inc., Nektar Pharmaceuticals Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc., Bristol-Myers Squibb Company, Eisai Inc., and Nanostring. Consultant/Steering Committee: Eli Lilly and Company, Odonate, and CytomX. Advisory board: Genentech/Roche, Immunomedics/Gilead, Puma, Sanofi, Kyowa Kirin Pharmaceuticals, Samsung Bioepsis Inc., Certara, Mersana Therapeutics, Ellipses Pharma, 4D Pharma, OncoSec Medical Incorporated, Silverback Therapeutics, G1 Therapeutics, Celldex, Inc., and BeyondSpring Pharmaceuticals. Contracted research: Cyclacel, Seattle Genetics, Inc., and Exelixis, Inc. Consultant: Daiichi- Sankyo, Inc., Athenex, OncoPep, and Chugai Pharma USA, LLC. Steering Committee: OncXerna. Kristen Whitaker, MD, MS, reported a financial interest/relationship or affiliation in the form of Consultant: Novartis Pharmaceuticals Corp.
The directors, planners, managers and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months: Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months. Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.
Target Audience
This educational activity is designed for the interprofessional care team comprised of medical oncologists, pathologists, surgeons, pharmacists, physician assistants, oncology nurses, social workers, and others involved with the overall care coordination for TNBC.
Learning Objectives
At the conclusion of this activity, participants should be better able to:
- Describe how health disparities contribute to inequalities in health outcomes in women with TNBC.
- Discuss the importance of adequate screening, genetic testing and diagnosis to facilitate early identification and treatment of TNBC among black women and other medically underserved minoritized populations in the United States.
- Identify black women with TNBC who may benefit from treatment with an antibody-drug conjugate or other novel therapy to help overcome disparities in care and promote health equity.
Accreditation and Credit Designation Statements
ACCREDITED CONTINUING EDUCATION
Accreditation Statement
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
Credit Designation for Physicians
AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit Designation for Physician Assistants
AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 01/18/2023. PAs should only claim credit commensurate with the extent of their participation.
Credit Designation for Pharmacists
This application-based activity is approved for 1.0 contact hour of continuing pharmacy education JA4008106-0000-21-078-H01-P.
Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
Laboratory Professionals
This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 1.0 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program.
Disclaimer
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Provider(s)/Educational Partner(s)
Provided by
Commercial Support
This activity is supported by an independent educational grant from Gilead.
System Requirements
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

- Lyudmila Bazhenova, MD
  Peer
- Benjamin Levy, MD
  Peer
2
CME/CE
The Emerging Role of HER2 (ERBB2) Mutations in NSCLC
The Emerging Role of HER2 (ERBB2) Mutations in NSCLC
0.25 credits
The Emerging Role of HER2 (ERBB2) Mutations in NSCLC
0.25 credits
- Andrew M. Brunner, MD
  Peer
- Amy E. DeZern, MD, MHS
  Peer
1
CME/CE
A New Light in Higher-Risk MDS: Emerging Treatment Options
A New Light in Higher-Risk MDS: Emerging Treatment Options
0.25 credits
A New Light in Higher-Risk MDS: Emerging Treatment Options
0.25 credits
- Larry Anderson, MD, PhD
  Peer
- Thomas G. Martin, MD
  Peer
2
CME/CE
State of the Union: CAR T Cell Therapy
State of the Union: CAR T Cell Therapy
0.25 credits
State of the Union: CAR T Cell Therapy
0.25 credits
- Jacqueline Garcia, MD
  Peer
- David A. Sallman, MD
  Peer
1
CME/CE
Keeping Pace with Hematologic Malignancies: Understanding, Classifying, and Stratifying MDS
Keeping Pace with Hematologic Malignancies: Understanding, Classifying, and Stratifying MDS
0.25 credits
Keeping Pace with Hematologic Malignancies: Understanding, Classifying, and Str…
0.25 credits